Inventor · disambiguated record
Esther Breij
Also filed as: BREIJ ESTHER · BREIJ ESTHER C W
13 granted patents·24 pending applications·55 citations·filing 2016–2025
90Inventor score
Top patents by PatentIndex Score
37 records- 0196US11608383B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Mar 21, 2023·8 cites·30 claims
- 0296US11535679B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Dec 27, 2022·8 cites·27 claims
- 0395US11845805B2Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphomaGENMAB AS·Filed 2021·Granted Dec 19, 2023·5 cites·33 claims
- 0495US11396553B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2021·Granted Jul 26, 2022·8 cites·23 claims
- 0594US11512137B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Nov 29, 2022·10 cites·10 claims
- 0694US11034772B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Jun 15, 2021·7 cites·20 claims
- 0793US11858995B2Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemiaGENMAB AS·Filed 2021·Granted Jan 2, 2024·4 cites·28 claims
- 0890US10882913B2Anti-DR5 antibodies and methods of use thereofGENMAB BV·Filed 2019·Granted Jan 5, 2021·4 cites·23 claims
- 0985US2024392032A1AntibodiesGENMAB AS·Filed 2024·Application pending·0 cites
- 1080US2024117064A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2022·Application pending·0 cites
- 1178US2024301078A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2023·Application pending·0 cites
- 1277US12448459B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2021·Granted Oct 21, 2025·0 cites·23 claims
- 1373US12247080B2Anti-DR5 antibodies and methods of use thereofGENMAB BV·Filed 2020·Granted Mar 11, 2025·0 cites·15 claims
- 1472US12275797B2Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereofGENMAB HOLDING B V·Filed 2019·Granted Apr 15, 2025·1 cites·18 claims
- 1571US2022324980A1AntibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 1671US2025340647A1AntibodiesGENMAB AS·Filed 2025·Application pending·0 cites
- 1769US2025066507A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2024·Application pending·0 cites
- 1869US2024228641A9Antibodies binding to cd30 and cd3GENMAB AS·Filed 2023·Application pending·0 cites
- 1968US2020277397A1AntibodiesGENMAB AS·Filed 2020·Application pending·0 cites
- 2068US2024034812A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 2167US2021292418A1AntibodiesGENMAB AS·Filed 2021·Application pending·0 cites
- 2264US2020270359A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING BV·Filed 2018·Application pending·0 cites
- 2363US2023312758A1Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 2463US2023357440A1Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 2561US2019144554A1Anti-dr5 antibodies and methods of use thereofGENMAB BV·Filed 2016·Application pending·0 cites
- 2659US2023399414A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2022·Application pending·0 cites
- 2759US2020199231A1Bispecific antibodies against cd3 and cd20GENMAB AS·Filed 2019·Application pending·0 cites
- 2857US2025382378A1Cd38 antibodies and uses thereofGENMAB AS·Filed 2023·Application pending·0 cites
- 2954US2021107980A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Application pending·0 cites
- 3053US2023293680A1A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myelomaGENMAB BV·Filed 2021·Application pending·0 cites
- 3151US2025302982A1Methods of treating cancer with anti-tissue factor antibody-drug conjugatesGENMAB AS·Filed 2023·Application pending·0 cites
- 3250US2023257479A1Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancerGENMAB AS·Filed 2020·Application pending·0 cites
- 3348US12453781B2Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Granted Oct 28, 2025·0 cites·36 claims
- 3448US2021308208A1Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancerGENMAB AS·Filed 2019·Application pending·0 cites
- 3546US2024252635A1Pharmaceutical compositions comprising bispecific anti-cd37 antibodiesGENMAB HOLDING B V·Filed 2019·Application pending·0 cites
- 3644US2023027495A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2020·Application pending·0 cites
- 3738US12324841B2Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Granted Jun 10, 2025·0 cites·28 claims
Join the waitlist — get patent alerts
Get an alert when Esther Breij files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →